20 new ADC drugs worldwide reached US$16.51 billion , a year-on-year increase of 27% , maintaining rapid growth. Six of these ADCs are blockbuster products with sales exceeding US$1 billion, including four super blockbuster products with sales exceeding US$2 billion.
Enhertu continues to maintain its monopoly position, and its indications continue to expand.Datroway saw a 50% quarter-over-quarter increase and significantly raised its sales forecast.Padcev has performed exceptionally well in the US and European markets, with growth exceeding expectations.Roche's T-DM1 has maintained steady growth, mainly due to the increase in adjuvant therapy for breast cancer.Polivy maintains rapid growth, solidifies its position as a leading DLBCL provider, and rapidly penetrates the market.

Trodelvy is primarily marketed as a second-line treatment for triple-negative breast cancer, with first-line treatment expected to be approved in the second half of this year.Conclusion

Chinese ADCs are playing an increasingly important role. BIC's Trop2 ADC has been approved for marketing, becoming the world's first approved Trop2 ADC for lung cancer treatment. Lepu Biopharma's world-first EGFR ADC has also been approved. Baili Tianheng's EGFR/HER3 ADC has submitted a marketing application, and Yingen Biopharma's HER2 ADC is expected to submit a marketing application in the United States in 2026.

https://news.yaozh.com/archive/47164.html